- Home
- FSFG vs CHRS Comparison
FSFG vs CHRS Comparison
Compare FSFG & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSFG
- CHRS
- Stock Information
- Founded
- FSFG 2008
- CHRS 2010
- Country
- FSFG United States
- CHRS United States
- Employees
- FSFG N/A
- CHRS N/A
- Industry
- FSFG Savings Institutions
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FSFG Finance
- CHRS Health Care
- Exchange
- FSFG Nasdaq
- CHRS Nasdaq
- Market Cap
- FSFG N/A
- CHRS 191.3M
- IPO Year
- FSFG 2008
- CHRS 2014
- Fundamental
- Price
- FSFG $24.77
- CHRS $1.47
- Analyst Decision
- FSFG Buy
- CHRS Strong Buy
- Analyst Count
- FSFG 1
- CHRS 4
- Target Price
- FSFG $31.00
- CHRS $5.38
- AVG Volume (30 Days)
- FSFG 12.8K
- CHRS 2.3M
- Earning Date
- FSFG 01-28-2025
- CHRS 11-06-2024
- Dividend Yield
- FSFG 2.39%
- CHRS N/A
- EPS Growth
- FSFG 66.39
- CHRS N/A
- EPS
- FSFG 1.98
- CHRS N/A
- Revenue
- FSFG $68,091,000.00
- CHRS $304,340,000.00
- Revenue This Year
- FSFG N/A
- CHRS $2.47
- Revenue Next Year
- FSFG $2.77
- CHRS N/A
- P/E Ratio
- FSFG $12.67
- CHRS N/A
- Revenue Growth
- FSFG N/A
- CHRS 44.19
- 52 Week Low
- FSFG $14.55
- CHRS $0.66
- 52 Week High
- FSFG $30.94
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- FSFG 34.50
- CHRS 50.55
- Support Level
- FSFG $25.25
- CHRS $1.35
- Resistance Level
- FSFG $27.17
- CHRS $1.77
- Average True Range (ATR)
- FSFG 0.88
- CHRS 0.13
- MACD
- FSFG -0.12
- CHRS -0.02
- Stochastic Oscillator
- FSFG 5.84
- CHRS 28.57
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.